argenx is committed to improving the lives of people suffering from severe autoimmune diseases and cancer. We aim to do this in partnership; by listening to patients, supporters and advocacy communities and hearing your stories. It is your words and your resilience that motivate us to advance the understanding of rare disease and work to deliver new treatments to as many patients as possible.

While we believe participation in a clinical trial is the most appropriate way to access investigational therapies, we understand that this is not possible for all patients. In these circumstances, argenx may consider making investigational therapies available outside of a clinical trial.

This is typically done through a pre-approval access program. Click below to learn about pre-approval access to argenx investigational therapies.
 

 

Information about argenx clinical trials can be found on clinicaltrials.gov.